#ovarian cancer

Squelching Ovarian Cancer: The Not-So-Silent Killer

Results of the SORAYA study show antibody-drug conjugate produced remissions in one-third of patients with drug-resistant ovarian cancer.

Advances in immunotherapy, new drug approvals and news about hard-to-treat cancers caught readers’ attention this year.

Elahere, a new antibody-drug conjugate, shrank tumors in about a third of treatment-experienced patients.

Black patients with ovarian cancer were less likely than their white counterparts to be treated according to NCCN guidelines.

Music teacher Winona Williams lives a life not dominated by her ovarian cancer diagnosis—and she hopes her treatment will help others.

September is Gynecologic Cancer Awareness Month.

September is Ovarian Cancer Awareness Month

The combination of target drugs Tafinlar-Mekinist is approved for nearly any type of advanced solid tumor that has the BRAF gene mutation.

A nutritionist who believes in the power of food and yoga to nourish the mind and body of cancer survivors

Becoming a patient advocate during her mom’s ovarian cancer journey led to her life’s work to improve the cancer experience.

Each 10% increase in state spending decreased racial disparities in five-year overall survival by 5%.

The virtual intervention was deemed appropriate and involved an acceptable time commitment.

Known as a carbon nanotube, the implant can detect cancer-associated proteins and alert a devise outside the body.

As an organization whose mission is to improve cancer care globally, NCCN stands in solidarity with the Ukrainian people.

Clinical testing of this approach in people with ovarian cancer is expected to start later this year.

A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.